Tirzepatide

What is Tirzepatide?

Tirzepatide (development code LY3298176) is a synthetic 39-amino-acid peptide with CAS registry number 2023788-19-2 and molecular formula C225H348N48O68. The pharmacological literature classifies it as a dual GIP and GLP-1 receptor agonist based on in vitro receptor studies. Nocap Research supplies it as a lyophilized reference material for laboratory research only.

Chemical Identity

Tirzepatide, also identified by the development code LY3298176, is a synthetic peptide composed of 39 amino acids. It is catalogued under CAS registry number 2023788-19-2 and is described by the molecular formula C225H348N48O68, with a molecular weight of approximately 4813.5 g/mol. In the pharmacological literature the molecule is classified as a dual receptor agonist, with reported activity at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. These are in vitro molecular characterizations and do not describe an effect in humans or animals. Nocap Research offers this compound solely as a reference material for in vitro laboratory investigation.

Specifications

Structure and Modifications

The tirzepatide backbone contains two non-proteinogenic 2-aminoisobutyric acid (Aib) residues, at positions 2 and 13. The lysine at position 20 carries a lipid side chain built from a C20 fatty diacid joined through a gamma-glutamic acid and oligo(ethylene glycol) linker, and the C-terminal serine is amidated.

Cryo-EM studies have resolved the peptide bound to the GIP and GLP-1 receptors, which is why it is frequently used as a reference compound in receptor structure and signaling research.

Physical Form, Handling, and Storage

The material is supplied as a lyophilized (freeze-dried) powder. As a laboratory reagent, lyophilized peptide is generally stored desiccated and protected from light, with long-term storage commonly at -20C or below and short-term working material at 2C to 8C. For laboratory work the powder is solubilized in a solvent chosen for the intended in vitro application. These notes describe general handling of the material as a research reagent. They are not instructions for use in humans or animals.

Purity and Certificate of Analysis

Every Nocap Research batch of Tirzepatide is tested by an independent laboratory before it is listed. The current batch results are below, transcribed from the certificate of analysis. The full certificate, and a link to verify it directly with the lab, are one click away.

How Nocap Research tests every batch and how to read a certificate of analysis.

Selected Scientific Literature

The peer-reviewed papers below characterize Tirzepatide at the level of chemistry, structure, synthesis or analytical method. These references describe scientific literature and are not evidence of safety or efficacy for use in humans or animals.

1. Willard FS et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020. Characterizes the peptide's signaling at the GIP and GLP-1 receptors in cell-based pharmacology assays. PMID 32730231 DOI 10.1172/jci.insight.140532
2. Sun B et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci U S A. 2022. Reports cryo-EM structures of the peptide bound to its receptors. PMID 35333651 DOI 10.1073/pnas.2116506119
3. Zhao F et al. Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors. Nat Commun. 2022. Describes receptor-bound structures of the peptide and a related peptide. PMID 35217653 DOI 10.1038/s41467-022-28683-0

Search PubMed for more Tirzepatide literature

Tirzepatide 10mg in the Catalog

Price, current stock and the batch certificate for Tirzepatide 10mg are listed on its product page. An account is required to purchase.

View Tirzepatide 10mg: price, stock and certificate of analysis

More in the Research Library